share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股SEC公告 ·  07/26 09:08
Moomoo AI 已提取核心信息
On July 23, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the amendment and restatement of the employment agreement with Martin Brenner, the company's CEO and Chief Scientific Officer. The new agreement, effective as of July 1, 2024, increases Dr. Brenner's base salary to $522,365 and raises his bonus target to 50% of his base salary for fiscal year 2025, while maintaining a 40% bonus target for fiscal year 2024. Dr. Brenner's employment remains at-will, and the agreement outlines standard and additional termination benefits, including severance payments and health insurance coverage under certain conditions. The agreement also includes provisions for the assignment of inventions and non-solicitation. The amended and restated employment agreement is attached to the filing as Exhibit 10.1.
On July 23, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the amendment and restatement of the employment agreement with Martin Brenner, the company's CEO and Chief Scientific Officer. The new agreement, effective as of July 1, 2024, increases Dr. Brenner's base salary to $522,365 and raises his bonus target to 50% of his base salary for fiscal year 2025, while maintaining a 40% bonus target for fiscal year 2024. Dr. Brenner's employment remains at-will, and the agreement outlines standard and additional termination benefits, including severance payments and health insurance coverage under certain conditions. The agreement also includes provisions for the assignment of inventions and non-solicitation. The amended and restated employment agreement is attached to the filing as Exhibit 10.1.
2024年7月23日,生物技术公司ibio inc在特拉华州成立,向美国证券交易委员会提交8-k表格,报告修改和重签与首席执行官兼首席科学官马丁·布伦纳的雇佣协议。新协议自2024年7月1日起生效,将布伦纳博士的基本薪水提高到522,365美元,并将他的2025财年奖金目标提高至其基本薪水的50%,同时保持2024财年40%的奖金目标。布伦纳博士的雇佣关系仍为自愿性质,并概述了标准及附加终止福利,包括在某些情况下的遣散补偿和健康保险政策。该协议还包括发明和非招揽分配的条款。修改和重签的雇佣协议附在提交的10.1展示中。
2024年7月23日,生物技术公司ibio inc在特拉华州成立,向美国证券交易委员会提交8-k表格,报告修改和重签与首席执行官兼首席科学官马丁·布伦纳的雇佣协议。新协议自2024年7月1日起生效,将布伦纳博士的基本薪水提高到522,365美元,并将他的2025财年奖金目标提高至其基本薪水的50%,同时保持2024财年40%的奖金目标。布伦纳博士的雇佣关系仍为自愿性质,并概述了标准及附加终止福利,包括在某些情况下的遣散补偿和健康保险政策。该协议还包括发明和非招揽分配的条款。修改和重签的雇佣协议附在提交的10.1展示中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息